Compare FBRT & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FBRT | VALN |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 695.9M | 653.3M |
| IPO Year | 2012 | 2021 |
| Metric | FBRT | VALN |
|---|---|---|
| Price | $7.48 | $6.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $11.50 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 1.8M | 27.1K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 15.83% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $270,071,000.00 | N/A |
| Revenue This Year | $12.34 | N/A |
| Revenue Next Year | $4.95 | $93.87 |
| P/E Ratio | $40.00 | ★ N/A |
| Revenue Growth | ★ 28.33 | N/A |
| 52 Week Low | $7.35 | $4.75 |
| 52 Week High | $11.35 | $12.23 |
| Indicator | FBRT | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 31.77 | 52.85 |
| Support Level | $7.35 | $6.29 |
| Resistance Level | $9.32 | $6.60 |
| Average True Range (ATR) | 0.23 | 0.22 |
| MACD | -0.10 | -0.08 |
| Stochastic Oscillator | 0.75 | 28.90 |
Franklin BSP Realty Trust Inc is a private real estate investment trust that originates, acquires, and manages a diversified portfolio of commercial real estate debt, and first mortgage loans. secured by properties located in the United States. The Company's operations are organized into two business units: (i) Commercial Real Estate Financing, and (ii) Agency Business. Its four reporting segments are as follows: The real estate debt business, The Agency Business, The commercial real estate conduit business, and The real estate owned business.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.